ArticleFrontiers in microbiology2026
Dual modulation of the NLRP3/CASPASE-1 inflammasome pathway and gut microbial metabolism: the antidepressant mechanism of puerarin.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke depression (PSD) is the most common neuropsychiatric complication following stroke. Puerarin (PU), the principal bioactive compound extracted from the medicinal and edible plant Methods: To investigate the ameliorative effect of PU on behavioral abnormalities and to clarify the role of intestinal microbiota regulation in the therapeutic effects of PU in PSD mice, various methodologies were employed, including a PSD model, behavioral tests, network pharmacology, hematoxylin-and-eosin staining, ultrastructural morphology, enzyme-linked immunosorbent assay, western blotting, 16S rRNA sequencing, metabolomic analyses, and fecal microbiota transplantation (FMT). Results: Oral administration of PU could effectively alleviate depressive-like behaviors in PSD mice, repair the damaged colonic mucosa, and increase the expression of occludin and ZO-1. Network pharmacology analysis indicated that the NLRP3/CASPASE-1 inflammasome pathway was a potential therapeutic target of PU, and PU inhibited activation of the hippocampal NLRP3/CASPASE-1 inflammasome. Additionally, PU suppressed pro-inflammatory cytokines in both the hippocampus and serum. PU restored the intestinal microbiota and regulated the microbial metabolism of PSD mice. More importantly, fecal microbiota transplantation from PSD mice reproduced depressive-like behaviors, while fecal microbiota transplantation from PU-treated mice (PU-FMT) prominently relieved depressive-like behaviors in PSD mice. Conclusion: Our findings indicate that PU reduces depressive-like behaviors in PSD mice by modulating the intestinal microbiota and microbial metabolism and inhibiting the NLRP3/CASPASE-1 inflammasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.